Waters Corp (WAT) Stock
Fundamentals
Source: third-party data provider, as of October 14, 2026
Compare with WAT
Recent news

Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
WAT

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
WAT

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT

Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.46
- MACD 12/26/9
- 5.11
- EMA 9 of MACD
- 6.41
- MACD histogram
- -1.30
- SMA 50
- $418.09
- Price above SMA 50
- EMA 50
- $415.81
- Price above EMA 50
- SMA 200
- $365.42
- Price above SMA 200
- EMA 200
- $380.13
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.29 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Here's Why You Should Retain WAT Stock in Your Portfolio for Now
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
WAT

Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
Waters Tops Growth Outlook as AI Demand, BD Integration Fuel Momentum
WAT

Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
Waters Launches BD FACSDiscover A7 for Advanced Flow Cytometry
WAT

Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Everlywell Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT

Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
Why Is Waters (WAT) Up 3.1% Since Last Earnings Report?
WAT

LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
LetsGetChecked Powered by Fuze Health Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
WAT

Waters Q2 Earnings Call Highlights
Waters Q2 Earnings Call Highlights
WAT

Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised
Waters Q2 Earnings Beat Estimates, 2026 Revenue Growth View Raised
WAT

Waters (WAT) Q2 Earnings and Revenues Beat Estimates
Waters (WAT) Q2 Earnings and Revenues Beat Estimates
WAT

Waters (WAT) Earnings Expected to Grow: Should You Buy?
Waters (WAT) Earnings Expected to Grow: Should You Buy?
WAT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Waters Corp
Waters is the world's leading specialty measurement company focused on improving human health and well-being through the application of high-value analytical technologies and industry leading scientific expertise. Waters has continually pioneered chromatography, mass spectrometry and thermal analysis innovations.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Udit Batra Ph.D. | President, CEO & Director | 1971 |
| Mr. Amol Chaubal | Senior VP & CFO | 1976 |
| Ms. Jianqing Y. Bennett | Senior Vice President of Waters Advanced Diagnostics Division | 1970 |
| Mr. Christos Ross | Senior Vice President of Global Operations | — |
| Mr. Brook M. Colangelo | Senior VP & Chief Information Officer | 1978 |
| Mr. Caspar Tudor | Head of Investor Relations | — |
| Ms. Keeley A. Aleman J.D. | Senior VP, General Counsel, Head of Global Human Resources & Corporate Secretary | 1977 |
| Ms. Kristen Garvey | Senior Vice President of Global Communications | — |
| Dr. Daniel Rush Ph.D. | Senior Vice President of Global Research & Strategy | — |
| Mr. Allan Jaenicke | Senior Vice President of Transformation | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 14, 2026
Technical indicators
- RSI 14
- 52.46
- MACD 12/26/9
- 5.11
- EMA 9 of MACD
- 6.41
- MACD histogram
- -1.30
- SMA 50
- $418.09
- Price above SMA 50
- EMA 50
- $415.81
- Price above EMA 50
- SMA 200
- $365.42
- Price above SMA 200
- EMA 200
- $380.13
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 13, 2026. Technical data, not a recommendation.
Analyst views
10 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $400.00
- Average
- $475.50
- High
- $515.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.6 | -10.0 | +13.4 | |||||||||
| 2022 | -12.2 | -2.2 | -1.0 | -1.8 | +8.5 | +2.9 | +8.1 | -18.3 | -10.3 | +7.9 | +12.7 | -1.3 |
| 2023 | -4.9 | -8.0 | +0.1 | -2.3 | -15.8 | +4.1 | +4.3 | +2.3 | -2.4 | -11.8 | +16.5 | +14.0 |
| 2024 | -3.3 | +4.0 | -0.5 | -10.3 | -2.2 | -6.4 | +19.0 | -1.8 | +5.9 | -9.8 | -0.6 | -4.2 |
| 2025 | +12.8 | -8.2 | -0.9 | -2.3 | +2.2 | +1.6 | -19.1 | +4.0 | +1.1 | +9.3 | +16.7 | -4.5 |
| 2026 | -2.9 | -15.8 | -3.1 | +3.1 | +24.9 | -0.8 | -0.2 | +10.6 | +8.3 | +1.5 |



